P-values of 0.05 or less were considered

statistically significant. Values are expressed as mean (range) ± standard deviation (SD) and percent of prescribed dose. Results The mean, minimum and maximum PTV doses before the bolus applications Y-27632 nmr were 101.8% (100.2–103.2%) ± 0.9%, 91.2% (90.0–94.5%) ± 1.2% and 109.4% (105.0–110.6%) ± 1.3%, respectively. Table 1 shows the mean, minimum, and maximum doses to the skin according to days of bolus application. These doses were significantly (p < 0.001) increased with increased days of bolus application. The CP-690550 cost mean, minimum and maximum doses to the skin structure with each bolus regimen and in each plan are shown in Figures 4, 5 and 6. Figure 4 Mean values of skin structure doses according to bolus frequencies for all plans. Figure 5 Minimum values of skin structure doses according to bolus frequencies for all plans. Figure 6 Maximum values of skin structure doses according to bolus frequencies for all plans. Table 1 Mean values of mean, minimum, and maximum skin structure doses according to bolus frequencies Bolus Regimen Mean ± SD* Minimum ± SD* Maximum ± SD* 0 100.0 ± 1.1 73.0 ± 2.0 110.1 ± 1.1 5 100.6 ± 1.1 78.2 ± 2.0 110.3 ± 1.1 10 101.3 ± 1.1 83.3 ± 1.7 110.5 ± 1.2 15

101.9 ± 1.1 88.3 ± 1.6 110.8 ± 1.3 20 102.6 ± 1.1 92.2 ± 1.7 111.2 ± 1.5 25 103.2 ± 1.1 93.8 ± 1.8 112.2 ± 1.7 * as percent of prescribed dose; SD, standard deviation Bolus use in all fractions provided a 20.8% ± 2.8% minimum skin dose increment. The minimum skin dose increments between 20 and 25 (1.6% ± 1.0%), and 15 and 20 (4.0% ± 1.0%) days of bolus applications were significantly lower than the dose increments between 0 and 5 (5.2% ± 0.6%), 5 and 10 (5.1% ± 0.8%), and 10 and 15 (4.9% ± 0.8%) days of bolus applications (p < 0.001). Furthermore, the minimum skin dose increment between 20 and 25 (1.6% ± 1.0%) days of bolus

application was lower than the dose increment between 15 and 20 (4.0% ± 1.0%) days of bolus application (p < 0.001). Bolus use in all fractions resulted in a 2.0% ± 1.2% maximum skin dose increment. The maximum skin 4-Aminobutyrate aminotransferase dose increments between 20 and 25 (1.0% ± 0.6%), and 15 and 20 (0.4% ± 0.3%) days of bolus applications were significantly higher than the dose increments between 0 and 5 (0.2% ± 0.2%), 5 and 10 (0.2% ± 0.2%), and 10 and 15 (0.2% ± 0.2%) days of bolus applications (p ≤ 0.003). Furthermore, the maximum skin dose increment between 20 and 25 (1.0% ± 0.6%) days of bolus application was higher than the dose increment between 15 and 20 (0.4% ± 0.3%) days of bolus application (p < 0.001). The dose increase of the mean values between all bolus frequencies was similar (p= 0.965). Measurements using EBT gafchromic film revealed that Precise PLAN®2.